These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 19406035)
1. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. Garcia-Velasco JA Reprod Biomed Online; 2009; 18 Suppl 2():71-5. PubMed ID: 19406035 [TBL] [Abstract][Full Text] [Related]
2. GnRH-agonist triggering to avoid ovarian hyperstimulation syndrome: a review of the evidence. Martinez MC; Ruiz FJ; García-Velasco JA Curr Drug Targets; 2013 Jul; 14(8):843-9. PubMed ID: 23614678 [TBL] [Abstract][Full Text] [Related]
3. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181 [TBL] [Abstract][Full Text] [Related]
12. Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome. Shrem G; Steiner N; Balayla J; Volodarsky-Perel A; Tannus S; Son WY; Dahan MH Reprod Biomed Online; 2019 Sep; 39(3):433-438. PubMed ID: 31320288 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961 [TBL] [Abstract][Full Text] [Related]
14. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146 [TBL] [Abstract][Full Text] [Related]
15. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Youssef MA; van Wely M; Hassan MA; Al-Inany HG; Mochtar M; Khattab S; van der Veen F Hum Reprod Update; 2010; 16(5):459-66. PubMed ID: 20354100 [TBL] [Abstract][Full Text] [Related]
16. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Fiedler K; Ezcurra D Reprod Biol Endocrinol; 2012 Apr; 10():32. PubMed ID: 22531097 [TBL] [Abstract][Full Text] [Related]
17. Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists. Busso CE; Garcia-Velasco J; Gomez R; Alvarez C; Simón C; Pellicer A Reprod Biomed Online; 2009 Jul; 19(1):43-51. PubMed ID: 19573289 [TBL] [Abstract][Full Text] [Related]
18. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Mourad S; Brown J; Farquhar C Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012103. PubMed ID: 28111738 [TBL] [Abstract][Full Text] [Related]
19. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139 [TBL] [Abstract][Full Text] [Related]
20. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review. Kalampokas T; Creatsas G; Kalampokas E Gynecol Endocrinol; 2013 Feb; 29(2):98-100. PubMed ID: 23110560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]